Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

Investigators will begin setting up the TRANSFORM trial in spring 2024, with study recruitment set to begin later in the year

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

All patients have been successfully dosed in the first cohort of patients, and the Safety Review Committee has granted approval for progression of the study to the second dose level of INKmune.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.

"We look forward to announcing initial efficacy and safety data from the study, which we expect will be at the end of this quarter," says Salim Yazji, MD.